Bioindustry Park and biopmed



Similar documents
Università di Padova (IT) Dept. of Industrial Engineering Date: from - to (month/year) September Innovation Marks: N.A.

Eudendron: an Innovative Biotech Start-up

Promoting hi-tech entrepreneurship through university -based technology incubatorssome thoughts coming from experience

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

The Commercialization of Technology Concepts into Medical Products

Automating Cell Biology Annual general meeting, September 7, Phase Holographic Imaging

How To Promote Agricultural Productivity And Sustainability


Valentina Gualato, Ph.D. Process Development Scientist

SIPBS Portfolio Entry

1_ The Italian Startup Ecosystem: "Who s Who" 2_ Investments in hi-tech startups in Italy. 3_ A selection of significant startups

Alain Schmitt Directorate General for Enterprise October 14 th, 2014

SME support under Horizon 2020 how to make it work

DMPK: Experimentation & Data

University of Medicine and Dentistry of New Jersey (UMDNJ)

Bridging Innovation and Business

ASSOBIOMEDICA AND BIOMEDICAL START-UPS. Vera Codazzi, Ph.D.

ELEFTHO : Supporting Business Incubators & technology parks.

Michele Genovese DG Research and Innovation Specific International Cooperation Activities

Project Management. Dissemination and Exploitation Services in Horizon 2020

M The Nucleus M The Cytoskeleton M Cell Structure and Dynamics

Milan: a rich region Province of Milan = 3.7 million inhabitants Italy s richest urban agglomeration & one of the wealthy OECD metro regions

THE BIOTECH & PHARMACEUTICAL INDUSTRY

Master of Science in Biomedical Sciences

An Introduction to Genomics and SAS Scientific Discovery Solutions

Molecular Biotechnology Master s Degree Program

Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science

Translational research infrastructure in Neurosciences /Bruxelles


The National Centre for Biomedical Engineering Science

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

How To Create A Successful Economy

9360/15 FMA/AFG/cb 1 DG G 3 C

8970/15 FMA/AFG/cb 1 DG G 3 C

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover

Join our scientific talent community

BIOSCIENCES COURSE TITLE AWARD

BS in Pharmaceutical Science (BSPS) degree program University of Rhode Island

Nanomedicine in Horizon 2020

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

BioTalentum Ltd. Hungary Prof. András Dinnyés Director

InnoEnterprise Project Declan Gordon Carroll

Dalla Ricerca all Impresa le Start up di IIT. Lorenzo De Michieli, Ph.D. Technology Transfer - Manager lorenzo.demichieli@iit.it

Harald Isemann. Vienna Brno Olomouc. Research Institute for Molecular Pathology

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics

How To Get A Grant From Kinesis

MSc in Toxicology. Master Degree Programme

Agenda. 2. How does it work? International network for Market assessment -> Mapping > R2B B2B I2B opportunities detection -> Match making events

College of Pharmacy & Pharmaceutical Sciences Graduate Catalog

EIT: a new approach to innovation in European innovation or created by us to be solved by us

Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research

Chapter 6. Financing of innovative entrepreneurs

Making the most of academic drug target discoveries

THE ITALIAN STARTUP AGENDA

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Report from the visiting commitee

BIOTECHNOLOGY. about biotechnology

European Molecular Biology Laboratory Case Example

GlycArt Biotechnology AG From Inception to trade sale and what happened after...

We use Reaxys intensively for hit identification, hit-to-lead and lead optimization.

MSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary

Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

1) SCOPE OF THE PROGRAM

Executive summary of the new Italian legislation on start-ups

STRENGTHENING NATIONAL SYSTEMS OF INNOVATION: THE IMPORTANCE OF NATIONAL COLLABORATION, INCUBATORS, ENTREPRENEURSHIP AND NICHE MANAGEMENT

Financing innovation. Operational Programme Enterprise and Innovation for Competitiveness : Ing. Marcela Příhodová EU Funds Section, MIT

October 17, Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

I TECH-OFF INFORMATION TECHNOLOGY SPIN-OFF. Giulio Giunti P. 1. Giulio Giunti, 5th February 2008

NUVISAN Pharma Services

Spinnovator Public Private Partnership for Spin-offs

Presented at: Jefferies 2015 Global Healthcare Conference

STRATEGY OF OPEN JOINT-STOCK COMPANY RUSNANO UNTIL 2020

Transcription:

Bioindustry Park and biopmed Fabrizio Conicella conicella@bioindustrypark.it / 1

CONTENTS Piemonte cluster and Bioindustry Park Silvano Fumero biopmed cluster initiative biopmed internationalisation strategy Cluster delivering values to companies BioXcluster / 2

ITALY: PIEMONTE REGION Ø 2.2 billion R&D investments Ø 1,000 R&D contracts Ø 220 R&D centers, 380 Labs Ø 6 Science & Technology Parks Ø 4 Universities Verbania Ø 4.4 M inhabitants Ø 123.4 billion GDP Ø 38.5 billion export Ø 467,500 companies Biella Novara 1 st region in Italy for: Ø Private R&D investment Ø Hi-tech patents Torino Cuneo Asti Vercelli Alessandria Ø Strong relationships with other European Regions / 3

BIOINDUSTRY PARK SILVANO FUMERO Ø Science Park focused on life sciences, created with the support of Regione Piemonte in the EU programs framework (beginning 90 s) Operational since 1998. Ø It hosts more than 30 organizations Ø Managing company of the Innovation Cluster biopmed Ø Member of national and international networks Offer 22.000 sqm labs, office spaces R&D shared facilities R&D scientific services (Able Biosciences initiatives) 1 incubator Consultancy in biomanagement Conference centre www.bioindustrypark.eu Bioindustry Park 2013 All Rights Reserved / 4

BIOINDUSTRY PARK SILVANO FUMERO AS A COMPANY ü Private company (limited company) with public majority ü 27 full time employees + around 10 project based contracts ü Around 5 Ml euro turnover Total assets 23 Ml euro (2012) ü Positive EBITDA and EBIT; / 5

BIOINDUSTRY PARK: A PLATFORM FOR COMPANY DEVELOPMENT General services for lessees Incubation and start-up R&D: exploitation of scientific results and scientific services Cluster development, TT and International projects / 6

BIOINDUSTRY PARK SILVANO FUMERO HOSTING ACTIVITIES Space and equipment Support for the access to public grants Management and IP support Training Congress Centre Complete package of services to facilitate start-up and company spin off at each development phase: Pre start-up support Start-up assistance Development assistance Way-out support / 7

BIOINDUSTRY PARK: HOSTED ORGANISATIONS NatiMab Bioindustry Park 2013 All Rights Reserved / 8

BIOINDUSTRY PARK SILVANO FUMERO: SCIENTIFC ACTIVITIES ü Scien=fic support and shared facili=es ü Tools for scien=fic results exploita=on ü Technology Transfer ü Added value scien=fic services ü GLP/GMP facili=es ü Partnership with Università di Torino (Imaging and chemistry) and CNR (proteomics) Bioindustry Park 2013 All Rights Reserved / 9

ABLE BIOSCIENCES: SCIENTIFIC SERVICE PROVIDER Discovery Preclinical development Target, MOA, POC, Phase I Phase II Phase III Phase IV Regulatory/development requirements SUPPORT FOR DRUG DISCOVERY & DEVELOPMENT Target validation, drug activity, MOA, POC e-admet studies Biomarker discovery and detection Custom synthesis Spin-off, start-up, SMEs Pharma / Biotech To reach faster the POC and to boost licensing opportunities Tools Customized cell-based assays Protein profiling - MALDI imaging Mass spectrometry LC-MS/MS Gene expression qpcr Immunoassays CRO ACTIVITIES ADMET studies Bioanalytical methods for drugs and biomarkers. Clinical stage companies To fulfil all Your regulatory and development requirements / 10

BIOINDUSTRY PARK SILVANO FUMERO: A SYSTEM TO SPEED UP PRODUCT DEVELOPMENT Research Preclinical Clinical Bioanaly1cs Biomarkers Cell & Mol. Toxicology Custom synthesis Bioanaly1cs Biomarkers Cell & Mol. Toxicology Bioanaly1cs Biomarkers Stem cells Cell & Mol Biology GMP Stem cells Compounds Labelling Injectable GMP Stem cells Compounds Labelling Injectable In vivo in rodents Preliminary PK Preliminary Tox In vivo in rodents PK Pharmacology Preclinical Imaging More of 50 different clients in the last 4 years.. / 11

Start- up creation: the «Discovery approach» Public funds Scientific results PPP Public-Private Partnership Seed/start-up money Business angels Infrastructures, general services, addedd value services,, business development Financing, networking and skills Venture Capitalists network Technology Transfer through start-up creation / 12

BIOINDUSTRY PARK SILVANO FUMERO: main results 99-11 Opening of Bioindustry Park Year zero (1999) 2013 data confirms 2011 data / 13

BIOINDUSTRY PARK: A PLATFORM FOR COMPANY DEVELOPMENT General services for lessees Incubation and start-up R&D: exploitation of scientific results and scientific services Cluster development, TT and International projects / 14

Ø A EU world class cluster dedicated to bio and medical technologies created in 2009 Ø First Italian cluster for performances (MEDALICS/POLICS 2012) Ø A core founder of the ALISEI (Advanced LIfe SciEnces in Italy) national cluster that involves 13 different actors Ø A shared smart approach to innovation: converging technologies Overlapping different technological knowledge to reach innovative solutions to ensure a better future Synergies with local clusters (ICT, New materials, textiles...), with EP and non EP clusters 200 health care 132 R&D centers 3924 scientists Companies, Universities, R&D centers, foundations BIOPMED CLUSTER INITIATIVE National & International Hubs 370+ ENLARGE COMMUNITY 80+ CORE MEMBERS The biopmed Community / 15

SMEs INTERNATIONALISATION AND THE CLUSTER ENVIRONMENT: BIOPMED APPROACH Governance Labeling Project building Working groups Community building Shared access to infrastructures (material / immaterial) R&D Projects Added value shared services Regional financing International networking International clusters Events organisation and participation, information, opportunities and support to single companies, universities and agencies in sectorial internationalisation Council of European Bioregions International projects International agreements Soft landing agreements / 16

THE CLUSTER ENVIRONMENT Clear Goal setting Local Mapping (scientific assets, market focus, technology used by companies, etc) Promotional material and smart participation to events Personal/organisational network Training/skills Marketing approach Strategy definition and sharing KPI/outputs www.biopmed.eu Bioindustry Park 2013 All Rights Reserved / 17

BIOPMED: PERFORMANCES Companies contacted and involved 350 Scientist contacted and involved 3500 Organizations formally and contractually linked Total output project building activities 82 143 Technical work-shops organized 34 Companies involved in internationalisation and international activities 147 Advanced services financed 15 Feasibility studies and R&D projects financed EU funded project ongoing and presented % of members involved in projects (cumulative) Overall value of initiatives linked to cluster activities Involvement in institutional advisory board external to the region 29 10 100% 20.860.231 4 Ø biopmed obtained the Bronze label by the European Secretariat for cluster Analysis Ø biopmed ranked 1 st in a national evaluation of clusters and science park related to performances Source: Dai distretti industriali ai poli di innovazione. L'Italia nel Mediterraneo, M. Ferarra, R. Mavilia EGEA, 2012 / 18

Genomics, Biochemistry, Molecular & cellular biology Diagnos1c & Theranos1cs Electronical, medical & laboratory equipment Medical biomaterials Medical technology & Biomedical engineering Func1onal food Microbiological consor1a Computer sciences Disease Preven1on ROTARIC ATHIMAG SAFE TAN SUN TAN PREVI IaRO; ROTARIC Nutratec; NutraPiem P- Arap; RiOrTec For1Lat; P- Claim P- Oryza; Donkeymilk Resican; SuJTe Nogluterbug MicoDiaBreast ARAS BACOSTE SafeNutrifood Prothesis, biomedical Devices/ instrumenta1on & drug delivery BIOBONE CARDIOMITRAL SWAP SiNplant Self exp. DES TINET; I.B.G. IPEEI BONEJECT KEME; BIOMAG PIEDMONT Dense- gas CRYO CRYOPHARMA NANOSTENT FIDIS BIOMICROFAB DESTINI; BIOMAG WILOP; JIGTO FACE; ORECO HEXEC NeuroVirtual3D Nuvola3D RICCAmente Regenera1ve Medicine MOSQUITO HYPERSPECTRA STELLA BICONerve TINET; I.B.G. QUANTADIPO BONEJECT PIEDMONT PLA scaffolds NanoStem B.B.S. FACE WEB BI Pharmaceu1cal TAB2 NOVADEP TLR7A; ERP NATIMAB ATHEROVAX PSSEIK Personalized Medicine MOSQUITO GNRs Pred_HEALTH FaPre P- MOSP Diagnos1c EPIgene1c screening NuGeSa FAST Beta- agonist detec1on DMS; Bioprotech ATHIMAG HYPERSPECTRA; STELLA; LOCHTECH MicroDiBi PROMOTECO BANP. TrCD; Idata E_LAB; FAST P- MOSP ) Veterinary FLUOMAG CANESTRO

SMEs INTERNATIONALISATION AND THE CLUSTER ENVIRONMENT: BIOPMED STRATEGY International positioning Learning and working with others Matching with peers Corporate positioning for FDI and reputation Segmentation of countries following market trends, mapping of local assets and synergies Working with the best clusters to learn and growth not to raise money Identification of complementary clusters (dimension, stage of growth, technical assets, etc) Sharing/selling know-how Consultancy/Transfer of know-how to potential/future partners/clients Delivering value for companies creating a platform for growth Quality as a KPI. Not interested in numbers but in be able to deliver added value to specific companies: possibility to evaluate results. Working with partners (local/ international) / 20

BIOPMED: INTERNATIONAL NETWORK AND PROJECTS FR: Lyonbiopole; ADEBAG; Eurobiomed; Genopole; I-Care DE: BioM; Technologiepark Heidelberg, biotop PL: Wrocław Center for S&T in Medicine ES: BioCAT; Parque Tecnologico di Vizkaia, BioCat IT: Toscana Life Sciences CH: BioAlps ; DK: MVA UK: One Nucleus; SWE: Stockolm Science City BioCulture Biolake, Biobay, Juke, ZhangJiang Scientific Park Technology Centre of New Jersey CBS FIPASE BioRio (ongoing) Israel BioNegev cluster; RAD FABA Federation of Asian Biotech Associations STC Bioindustry Park 2013 All Rights Reserved / 21

CLUSTER INTERNATIONALISATION THROUGH A PARTNERSHIP BASED APPROACH To develop a common and joint internationalisation strategy for the 4 Life Sciences Clusters to reinforce European SMEs competitiveness beyond Europe Mutualising and sharing internationalisation tools (programs, practices, networks) already implemented to obtain economy of scale/knowledge www.bioxcluster.com Identifying the most efficient tools for SMEs competitiveness on the global market Testing common pilot actions towards 3 targeted markets: Brazil, China, United States Reinforcing the visibility of the 4 European Life Sciences Clusters together and European competences worldwide ERAI (Rhône-Alpes, FR) Project Leader Lyonbiopole (Rhône-Alpes, FR) Host Cluster BioCat (Catalonia, SP) Invited Cluster BioM (Bayern Region, DE) Invited Cluster BioPmed (Piedmont, IT) Invited Cluster / 22

BIOPMED AND INTERNATIONALISATION STRATEGIES: WHAT WE ARE LOOKING FOR, WHAT WE ARE OFFERING...? Ø Companies interested in developing their activities in Italy: technology scouting, soft landing, R&D, scientific services, managerial consulting, investments, etc Ø Incubators, science parks and clusters interested in developing win-win approaches to support in a reciprocal way our companies Ø Science parks, incubators and companies interested in our know how Ø Investors (Seed, corporate funds and VCs) to develop innovative way to finance high growth start-ups Ø Universities and R&D centers interested in exploiting their knowledge in our cluster / 23

BIO-EUROPE SPRING 2014 BIO-Europe Spring will be organised in Turin (Piemonte) March 10 12, 2014 http://www.ebdgroup.com/bes/program/index.php / 24

Is the team that win not the single player..! Bioindustry Park Silvano Fumero S.p.A. Fabrizio Conicella Director Business Development and Interna1onal projects conicella@bioindustrypark.it Via Ribes, 5 10010 Collerefo Giacosa (TO) Italy Tel. +39-0125- 561311 Fax +39-0125- 538350 info@biopmed.eu www.biopmed.eu www.bioindustrypark.eu